Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

Exclusion Criteria

• •Have a pre-existing central nervous system (CNS) condition (including, but not limited to, history of stroke or dementia) that, in the participating physician's judgment, would preclude participation in the study
• •Have known mental illness including, but not limited to, major depressive disorder, general anxiety disorder, or bipolar disorder that, in the participating physician's opinion, could significantly confound the patient-reported outcome (PRO) assessments
• •Have a history of or ongoing seizure disorder
• •Have severe hepatic impairment (Child-Pugh Class C)
• •Have an active infection (example, human immunodeficiency virus \[HIV\], viral hepatitis) or other medical condition that would contraindicate the use of prednisone/prednisolone (systemic glucocorticoid)
• •Have known alcohol or other substance abuse disorder
• •Are routinely taking medication-including, but not limited to, over-the-counter medications, supplements, medical marijuana or prescription pain medication-that is known to cause mental confusion or sedation or are using any of the medications
• •Are routinely taking systemic glucocorticoids (example, prednisone, prednisolone, dexamethasone) at a dosage higher than the equivalent of prednisone 10 milligram (mg) daily
• •Are currently using or have previously used chemotherapy for any cancer including mCRPC
• •Are concurrently using any first-generation androgen-receptor blocker (example, bicalutamide, flutamide, nilutamide) for mCRPC
• •Have previously taken enzalutamide or abiraterone acetate with prednisone
• •Are not capable of completing tests using a computerized system or completing a participant survey